AIMS: Chronic obstructive pulmonary disease with alveolar hypoxia is associated with diastolic dysfunction in the right and left ventricle (LV). LV diastolic dysfunction is not caused by increased afterload, and we recently showed that reduced phosphorylation of phospholamban at serine (Ser) 16 may explain the reduced relaxation of the myocardium. Here, we study the mechanisms leading to the hypoxia-induced reduction in phosphorylation of phospholamban at Ser16. METHODS AND RESULTS: In C57Bl/6j mice exposed to 10% oxygen, signalling molecules were measured in cardiac tissue, sarcoplasmic reticulum (SR)-enriched membrane preparations, and serum. Cardiomyocytes isolated from neonatal mice were exposed to interleukin (IL)-18 for 24 h. The beta-adrenergic pathway in the myocardium was not altered by alveolar hypoxia, as assessed by measurements of beta-adrenergic receptor levels, adenylyl cyclase activity, and subunits of cyclic AMP-dependent protein kinase. However, alveolar hypoxia led to a significantly higher amount (124%) and activity (234%) of protein phosphatase (PP) 2A in SR-enriched membrane preparations from LV compared with control. Serum levels of an array of cytokines were assayed, and a pronounced increase in IL-18 was observed. In isolated cardiomyocytes, treatment with IL-18 increased the amount and activity of PP2A, and reduced phosphorylation of phospholamban at Ser16 to 54% of control. CONCLUSION: Our results indicate that the diastolic dysfunction observed in alveolar hypoxia might be caused by increased circulating IL-18, thereby inducing an increase in PP2A and a reduction in phosphorylation of phospholamban at Ser16.
AIMS: Chronic obstructive pulmonary disease with alveolar hypoxia is associated with diastolic dysfunction in the right and left ventricle (LV). LV diastolic dysfunction is not caused by increased afterload, and we recently showed that reduced phosphorylation of phospholamban at serine (Ser) 16 may explain the reduced relaxation of the myocardium. Here, we study the mechanisms leading to the hypoxia-induced reduction in phosphorylation of phospholamban at Ser16. METHODS AND RESULTS: In C57Bl/6j mice exposed to 10% oxygen, signalling molecules were measured in cardiac tissue, sarcoplasmic reticulum (SR)-enriched membrane preparations, and serum. Cardiomyocytes isolated from neonatal mice were exposed to interleukin (IL)-18 for 24 h. The beta-adrenergic pathway in the myocardium was not altered by alveolar hypoxia, as assessed by measurements of beta-adrenergic receptor levels, adenylyl cyclase activity, and subunits of cyclic AMP-dependent protein kinase. However, alveolar hypoxia led to a significantly higher amount (124%) and activity (234%) of protein phosphatase (PP) 2A in SR-enriched membrane preparations from LV compared with control. Serum levels of an array of cytokines were assayed, and a pronounced increase in IL-18 was observed. In isolated cardiomyocytes, treatment with IL-18 increased the amount and activity of PP2A, and reduced phosphorylation of phospholamban at Ser16 to 54% of control. CONCLUSION: Our results indicate that the diastolic dysfunction observed in alveolar hypoxia might be caused by increased circulating IL-18, thereby inducing an increase in PP2A and a reduction in phosphorylation of phospholamban at Ser16.
Authors: Honey B Golden; Linley E Watson; Damir Nizamutdinov; Hao Feng; Fnu Gerilechaogetu; Hind Lal; Suresh K Verma; Swagoto Mukhopadhyay; Donald M Foster; Wolfgang H Dillmann; David E Dostal Journal: Int J Cardiol Date: 2013-07-30 Impact factor: 4.164
Authors: Juan Carlos Caraballo; Cecilia Yshii; Maria L Butti; Whitney Westphal; Jennifer A Borcherding; Chantal Allamargot; Alejandro P Comellas Journal: Am J Physiol Lung Cell Mol Physiol Date: 2011-01-21 Impact factor: 5.464
Authors: Kumar Kotlo; Keven R Johnson; Jean M Grillon; David L Geenen; Pieter deTombe; Robert S Danziger Journal: J Proteomics Date: 2012-05-31 Impact factor: 4.044
Authors: Uwe Kirchhefer; Christiane Brekle; John Eskandar; Gunnar Isensee; Dana Kučerová; Frank U Müller; Florence Pinet; Jan S Schulte; Matthias D Seidl; Peter Boknik Journal: J Biol Chem Date: 2014-10-15 Impact factor: 5.157
Authors: Sally H Vitali; Angeles Fernandez-Gonzalez; Janhavi Nadkarni; April Kwong; Chase Rose; S Alex Mitsialis; Stella Kourembanas Journal: Am J Physiol Lung Cell Mol Physiol Date: 2019-10-30 Impact factor: 5.464
Authors: Trond Brattelid; Eirik Qvigstad; Lise R Moltzau; Silje V S Bekkevold; Dagny L Sandnes; Jon Arne K Birkeland; Tor Skomedal; Jan-Bjørn Osnes; Ivar Sjaastad; Finn Olav Levy Journal: PLoS One Date: 2012-09-20 Impact factor: 3.240
Authors: Paul J M Wijnker; Peter Boknik; Ulrich Gergs; Frank U Müller; Joachim Neumann; Cris dos Remedios; Wilhelm Schmitz; Jürgen R Sindermann; Ger J M Stienen; Jolanda van der Velden; Uwe Kirchhefer Journal: J Muscle Res Cell Motil Date: 2011-09-30 Impact factor: 2.698
Authors: Camilla Udjus; Ivar Sjaastad; Ulla Hjørnholm; Torbjørn K Tunestveit; Pavel Hoffmann; Alexis Hinojosa; Emil K S Espe; Geir Christensen; Ole H Skjønsberg; Karl-Otto Larsen; Morten Rostrup Journal: Physiol Rep Date: 2022-02